Softwr

Healthcare · head to head

Aidoc vs Lunit

Aidoc logo

Aidoc

Healthcare

FDA cleared radiology AI for triage and notification of time critical findings

From
On request
Rated
-
Full reviewWebsite
Lunit logo

Lunit

Healthcare

FDA cleared and CE marked AI for mammography, tomosynthesis and chest radiography

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Aidoc the clearances are for triage and notification in the CADt category, so the software may reorder a worklist but may not deliver a diagnosis or replace a read, and business cases built on reduced radiologist workload do not survive contact with the regulatory wording.; Lunit the regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.
  • They diverge on capability: Aidoc covers Triage and notification, Lunit covers Lunit INSIGHT MMG.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Aidoc and Lunit actually diverge.

Attributes where Aidoc and Lunit differ
AttributeAidocLunit
PlatformsWeb, iOS, AndroidWeb

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Aidoc

  • Triage and notification
  • Intracranial haemorrhage
  • Pulmonary embolism
  • Large vessel occlusion
  • Pneumothorax on X-ray
  • aiOS platform
  • Clinical workflow notifications

Only in Lunit

  • Lunit INSIGHT MMG
  • Lunit INSIGHT DBT
  • Lunit INSIGHT CXR
  • Volpara density assessment
  • Volpara RiskPathways
  • Volpara dose tracking
  • PACS and mammography workstation integration

What people use each for

The jobs each tool is most often brought in to do.

Aidoc

  • A regional stroke centre that wants large vessel occlusion flagged and the neurointervention team notified before the radiologist dictatesnot Lunit
  • A trauma centre wanting cervical spine fracture and intra abdominal free gas prioritised in an overnight queue read by one on call radiologistnot Lunit
  • An oncology imaging programme that wants incidental pulmonary embolism caught on staging CTs ordered for a different questionnot Lunit
  • A health system that has bought AI from several vendors and wants one PACS integration through aiOS rather than one integration per algorithmnot Lunit

Lunit

  • A national breast screening programme evaluating AI as a second reader to reduce double reading workload where two human readers are currently mandatednot Aidoc
  • A breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on DBT specificallynot Aidoc
  • An American breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what Volpara is bought fornot Aidoc
  • A tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise filmsnot Aidoc

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Aidoc

  • The clearances are for triage and notification in the CADt category, so the software may reorder a worklist but may not deliver a diagnosis or replace a read, and business cases built on reduced radiologist workload do not survive contact with the regulatory wording.
  • Triage algorithms are tuned for sensitivity, so false positives are routine, and each one interrupts a radiologist. Sites that do not measure positive predictive value in their own case mix see clinician trust erode within months.
  • Pricing is per algorithm and per study volume with no published rate card, so the cost of a multi algorithm deployment escalates sharply and cannot be benchmarked before a sales conversation.
  • The clinical benefit accrues to stroke, trauma and cardiology service lines while the cost usually lands in the radiology or IT budget, which makes internal funding harder than the return on investment slides suggest.
  • Performance depends on scanner protocols and reconstruction settings, so results validated at one site do not transfer, and each deployment needs local validation work that is rarely budgeted for.

Lunit

  • The regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.
  • Detection AI changes recall rates in screening, and the downstream cost of additional diagnostic workup lands on the programme rather than on the software budget, which is the cost most screening business cases omit.
  • Performance is sensitive to the mammography vendor and acquisition protocol, so published results from a Hologic estate do not transfer to a GE or Siemens estate without local validation the buyer must fund.
  • MMG, DBT and CXR are licensed separately and Volpara modules are separate again, so a breast centre wanting detection, density and risk pathways is assembling four line items rather than buying one product.
  • Using AI as a replacement for one of two human readers is a workforce and liability decision that regulators and professional bodies treat differently in each country, so the saving that justifies the purchase may not be permitted where you operate.

Pricing, plan by plan

Aidoc

On request
  • Aidoc$undefined/year
    • Annual subscription priced by algorithm and by study volume
    • aiOS platform integration licensed separately from individual algorithms
    • Multi algorithm bundles negotiated for enterprise deployments

Lunit

On request
  • Lunit INSIGHT$undefined/year
    • Priced per study or per annual examination volume by product
    • MMG, DBT and CXR licensed separately
    • Volpara density and RiskPathways modules quoted separately

Which should you pick?

Choose Aidoc if

  • You need triage and notification.
  • You work on Web, iOS, Android.
  • You also want intracranial haemorrhage.
Aidoc review

Choose Lunit if

  • You need lunit insight mmg.
  • You also want lunit insight dbt.
Lunit review

Questions people ask

Is Aidoc or Lunit better?
Neither clearly leads. Aidoc starts at On request and Lunit at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Aidoc or Lunit?
Aidoc starts at On request and Lunit at On request.
Does Aidoc or Lunit run on more platforms?
Aidoc runs on Web, iOS, Android. Lunit runs on Web.
What is Aidoc best used for?
Aidoc is most often used for a regional stroke centre that wants large vessel occlusion flagged and the neurointervention team notified before the radiologist dictates, a trauma centre wanting cervical spine fracture and intra abdominal free gas prioritised in an overnight queue read by one on call radiologist, an oncology imaging programme that wants incidental pulmonary embolism caught on staging cts ordered for a different question, a health system that has bought ai from several vendors and wants one pacs integration through aios rather than one integration per algorithm. Of those, a regional stroke centre that wants large vessel occlusion flagged and the neurointervention team notified before the radiologist dictates and a trauma centre wanting cervical spine fracture and intra abdominal free gas prioritised in an overnight queue read by one on call radiologist are not what Lunit is typically brought in for.
What can Aidoc do that Lunit cannot?
Aidoc covers Triage and notification, Intracranial haemorrhage, Pulmonary embolism, Large vessel occlusion. Lunit covers Lunit INSIGHT MMG, Lunit INSIGHT DBT, Lunit INSIGHT CXR, Volpara density assessment.

Answered from the vendors’ own pages

Aidoc: Is Aidoc FDA cleared?

Yes, it holds multiple 510(k) clearances, but they are for computer aided triage and notification. It may prioritise a worklist and notify a team. It may not provide a diagnostic interpretation or replace a radiologist read.

Lunit: Is Lunit FDA cleared?

Yes for specific products. INSIGHT MMG, INSIGHT DBT and INSIGHT CXR Triage hold FDA 510(k) clearances. INSIGHT Risk, the five year risk prediction model, has been filed but was not cleared at the time of writing.

Aidoc: Does it reduce radiologist workload?

No. Every study still needs a full read. The benefit is in the order studies are read and how quickly a receiving specialty is activated, not in reading fewer studies.

Lunit: Can Lunit replace a second human reader in screening?

That depends entirely on your jurisdiction and professional body guidance, not on the software. The CE mark permits clinical use; it does not authorise a workforce model.

Aidoc: Can I run other vendors AI through it?

Yes, that is what the aiOS platform layer is for, and for health systems with several AI vendors it is often the main reason to buy Aidoc at all.

Lunit: What did the Volpara acquisition add?

Volumetric breast density measurement, dose tracking and RiskPathways high risk programme management, which are the things American breast centres buy for density notification compliance rather than for detection.

Aidoc: Is pricing published?

No. It is quoted per algorithm and by annual study volume, and enterprise bundles are negotiated case by case.

Lunit: Is pricing published?

No. It is quoted per study or per annual volume, by product, with on premises and cloud priced differently.

Share

Related pages

More on Aidoc

More on Lunit

Keep looking

Other head to heads